StockNow
Calendar
Log in
U.S. Markets

Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer

StockNow breaking-news AI analysis

Abbott’s headline reports a 30% absolute sensitivity improvement for Oncodetect in colorectal cancer, but supplied evidence lacks the comparator and study details.

1 stocks
ABTAbbott Laboratories$102.12Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

While Washington continues to exert economic pressure on Tehran, an American media report says that the US is considering a scenario of several days of attacks on Iran; a scenario that includes missile, drone, energy and nuclear facilities, ILNA reports

Geopolitics

"Missile launch by the Yemeni Armed Forces towards Saudi interests", Sabereen reports

U.S. Markets

American Express (AXP) Q3 2026 (USD): EPS 5.42 (exp. 4.50), Revenue 20.1bln (exp. 20.1bln)

AXP